In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope
about
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display librariesDiverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV PseudotypeIsolation of monoclonal antibodies with predetermined conformational epitope specificityNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyIn-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plantsMutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity.A vaccine for HIV type 1: the antibody perspective.Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same siteMolecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
P2860
Q27469875-5B33BF57-425E-4F46-BF13-A8C7CA72BA69Q27472930-2184498F-D924-45CA-9081-D973165286BAQ28728170-D8E0557A-D696-46C5-A853-5BD37AE1B116Q30431941-63422E15-D709-491D-A36C-96037FFC66D7Q31016954-A5700E16-9851-4E88-8FDA-D0B0FD364287Q33205911-C1F41041-D209-4B14-8BA5-F4D535EAB320Q33688229-D92A3547-7039-49D2-9295-DD81A232CEB8Q33725718-B3C3DB00-C31A-45E3-8F82-1DEF55978B0BQ33835295-543E5BF1-78AD-4A11-AFCA-188ACC8FD1F3Q33870236-8807D3A0-6384-4E73-9B5C-16683836CCD3Q34849268-39B16DF7-C947-447B-94E1-17732A684A6FQ35052938-01CE77E4-7E02-45B8-AE32-CFADC45A1F5FQ36037760-A83CB1C2-6785-4072-A0BB-AA15DDF55029Q36565346-369EF5E3-A092-4DCC-BC5E-02277D7F8DCFQ37456354-26388F96-A35E-4363-B6CA-7961DD69D0BAQ39684388-1163980F-885D-4DF0-8D97-C84FBF3E7E5EQ39698363-A610B553-7910-4580-A01E-52ABBE932AECQ39699375-605A799D-A879-48D7-9E26-E38A01EB9C4DQ39748810-D1472D3E-2C57-4835-A13B-03712568FBC6
P2860
In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@ast
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@en
type
label
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@ast
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@en
prefLabel
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@ast
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@en
P2093
P2860
P1433
P1476
In vitro antigen challenge of ...... ficiency virus type 1 envelope
@en
P2093
A F Labrijn
C F Barbas
D R Burton
H J Ditzel
J M Binley
P Fisicaro
P W Parren
P2860
P304
P407
P577
1996-12-01T00:00:00Z